{
    "xml": "<topic id=\"PHP2247\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/prochlorperazine\" basename=\"prochlorperazine\" title=\"PROCHLORPERAZINE\">\n<title>PROCHLORPERAZINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_382\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/prochlorperazine\">Prochlorperazine</xref>\n</p>\n<data name=\"vtmid\">79129001</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_182743901\" title=\"Antipsychotics (first-generation)\">Antipsychotics (first-generation)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP55845\" outputclass=\"indicationsAndDose\" rev=\"1.53\" parent=\"/drugs/prochlorperazine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Schizophrenia and other psychoses</p>\n<p outputclass=\"therapeuticIndication\">Mania</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12.5&#8239;mg twice daily for 7 days, dose to be adjusted at intervals of 4&#8211;7 days according to response; usual dose 75&#8211;100&#8239;mg daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12.5&#8211;25&#8239;mg 2&#8211;3 times a day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Short-term adjunctive management of severe anxiety</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8211;20&#8239;mg daily in divided doses; maximum 40&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting, acute attack</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 20&#8239;mg, then 10&#8239;mg after 2&#8239;hours.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12.5&#8239;mg as required, to be followed if necessary after 6 hours by an oral dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting, prevention</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8211;10&#8239;mg 2&#8211;3 times a day.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>12.5&#8239;mg as required, to be followed if necessary after 6 hours by an oral dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention and treatment of nausea</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;11 years (body-weight 10 kg and above)</p>\n<p>250&#8239;micrograms/kg 2&#8211;3 times a day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>5&#8211;10&#8239;mg up to 3 times a day if required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;4 years</p>\n<p>1.25&#8211;2.5&#8239;mg up to 3 times a day if required.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;11 years</p>\n<p>5&#8211;6.25&#8239;mg up to 3 times a day if required.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>12.5&#8239;mg up to 3 times a day if required.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Labyrinthine disorders</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>5&#8239;mg 3 times a day, increased if necessary to 30&#8239;mg daily in divided doses, dose to be increased gradually, then reduced to 5&#8211;10&#8239;mg daily, dose is reduced after several weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nausea and vomiting in previously diagnosed migraine</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth using buccal tablet</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>3&#8211;6&#8239;mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>3&#8211;6&#8239;mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>Doses are expressed as prochlorperazine maleate or mesilate; 1&#8239;mg prochlorperazine maleate &#8801; 1&#8239;mg prochlorperazine mesilate.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55753\" outputclass=\"unlicensedUse\" rev=\"1.16\" parent=\"/drugs/prochlorperazine\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use in children</p>\n<p>Injection not licensed for use in children.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">buccal</ph> use in children</p>\n<p>Buccal tablets not licensed for use in children.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55901\" outputclass=\"contraindications\" rev=\"1.35\" parent=\"/drugs/prochlorperazine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Avoid oral route in child under 10&#8239;kg</ph>; <ph outputclass=\"contraindication\">children (in psychotic disorders)</ph>; <ph outputclass=\"contraindication\">CNS depression</ph>; <ph outputclass=\"contraindication\">comatose states</ph>; <ph outputclass=\"contraindication\">phaeochromocytoma</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55917\" outputclass=\"cautions\" rev=\"1.22\" parent=\"/drugs/prochlorperazine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Elderly</ph> (in adults); <ph outputclass=\"caution\">hypotension (more likely after intramuscular injection)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55786\" outputclass=\"sideEffects\" rev=\"1.26\" parent=\"/drugs/prochlorperazine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dystonic reactions</ph>; <ph outputclass=\"sideEffect\">respiratory depression may occur in susceptible patients</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Acute dystonic reactions</p>\n<p>Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55827\" outputclass=\"pregnancy\" parent=\"/drugs/prochlorperazine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55923\" outputclass=\"breastFeeding\" parent=\"/drugs/prochlorperazine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p>\n<p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p>\n<p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p>\n<p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55862\" outputclass=\"hepaticImpairment\" parent=\"/drugs/prochlorperazine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55804\" outputclass=\"renalImpairment\" parent=\"/drugs/prochlorperazine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55945\" outputclass=\"directionsForAdministration\" rev=\"1.10\" parent=\"/drugs/prochlorperazine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">buccal</ph> use</p>\n<p>Buccal tablets are placed high between upper lip and gum and left to dissolve.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55817\" outputclass=\"patientAndCarerAdvice\" rev=\"1.14\" parent=\"/drugs/prochlorperazine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">buccal</ph> use</p>\n<p>Patients or carers should be given advice on how to administer prochlorperazine buccal tablets.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2247-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/prochlorperazine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: suppository</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74816\" title=\"Tablet\" namespace=\"/drugs/prochlorperazine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74803\" title=\"Buccal tablet\" namespace=\"/drugs/prochlorperazine/buccal-tablet\">Buccal tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74823\" title=\"Oral solution\" namespace=\"/drugs/prochlorperazine/oral-solution\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74838\" title=\"Solution for injection\" namespace=\"/drugs/prochlorperazine/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107735\" namespace=\"/guidance/prescribing-in-palliative-care\" title=\"Prescribing in palliative care\" count=\"1\" rel=\"backlink\">Prescribing in palliative care</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"2\" rel=\"backlink\">Psychoses and related disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78221\" namespace=\"/treatment-summaries/nausea-and-labyrinth-disorders\" title=\"Nausea and labyrinth disorders\" count=\"7\" rel=\"backlink\">Nausea and labyrinth disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"1\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_382\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/phenothiazines/prochlorperazine\" title=\"Prochlorperazine\" count=\"1\" rel=\"link\">Prochlorperazine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74816\" namespace=\"/drugs/prochlorperazine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74803\" namespace=\"/drugs/prochlorperazine/buccal-tablet\" title=\"Buccal tablet\" count=\"1\" rel=\"link\">Buccal tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74823\" namespace=\"/drugs/prochlorperazine/oral-solution\" title=\"Oral solution\" count=\"1\" rel=\"link\">Oral solution</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74838\" namespace=\"/drugs/prochlorperazine/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP2247",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/prochlorperazine",
    "basename": "prochlorperazine",
    "title": "PROCHLORPERAZINE",
    "interactants": [
        {
            "id": "bnf_int_382",
            "label": "Prochlorperazine"
        }
    ],
    "vtmid": "79129001",
    "drugClassification": [
        "Antipsychotics (first-generation)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Schizophrenia and other psychoses",
                        "html": "Schizophrenia and other psychoses"
                    },
                    {
                        "textContent": "Mania",
                        "html": "Mania"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "12.5 mg twice daily for 7 days, dose to be adjusted at intervals of 4&#8211;7 days according to response; usual dose 75&#8211;100 mg daily.",
                        "html": "<p>12.5&#8239;mg twice daily for 7 days, dose to be adjusted at intervals of 4&#8211;7 days according to response; usual dose 75&#8211;100&#8239;mg daily.</p>"
                    },
                    {
                        "textContent": "12.5&#8211;25 mg 2&#8211;3 times a day.",
                        "html": "<p>12.5&#8211;25&#8239;mg 2&#8211;3 times a day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Short-term adjunctive management of severe anxiety",
                        "html": "Short-term adjunctive management of severe anxiety"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "15&#8211;20 mg daily in divided doses; maximum 40 mg per day.",
                        "html": "<p>15&#8211;20&#8239;mg daily in divided doses; maximum 40&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting, acute attack",
                        "html": "Nausea and vomiting, acute attack"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 20 mg, then 10 mg after 2 hours.",
                        "html": "<p>Initially 20&#8239;mg, then 10&#8239;mg after 2&#8239;hours.</p>"
                    },
                    {
                        "textContent": "12.5 mg as required, to be followed if necessary after 6 hours by an oral dose.",
                        "html": "<p>12.5&#8239;mg as required, to be followed if necessary after 6 hours by an oral dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting, prevention",
                        "html": "Nausea and vomiting, prevention"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "5&#8211;10 mg 2&#8211;3 times a day.",
                        "html": "<p>5&#8211;10&#8239;mg 2&#8211;3 times a day.</p>"
                    },
                    {
                        "textContent": "12.5 mg as required, to be followed if necessary after 6 hours by an oral dose.",
                        "html": "<p>12.5&#8239;mg as required, to be followed if necessary after 6 hours by an oral dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention and treatment of nausea",
                        "html": "Prevention and treatment of nausea"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "250 micrograms/kg 2&#8211;3 times a day.",
                        "html": "<p>250&#8239;micrograms/kg 2&#8211;3 times a day.</p>",
                        "ageGroup": "1&#8211;11 years (body-weight 10 kg and above)"
                    },
                    {
                        "textContent": "5&#8211;10 mg up to 3 times a day if required.",
                        "html": "<p>5&#8211;10&#8239;mg up to 3 times a day if required.</p>",
                        "ageGroup": "12&#8211;17 years"
                    },
                    {
                        "textContent": "1.25&#8211;2.5 mg up to 3 times a day if required.",
                        "html": "<p>1.25&#8211;2.5&#8239;mg up to 3 times a day if required.</p>",
                        "ageGroup": "2&#8211;4 years"
                    },
                    {
                        "textContent": "5&#8211;6.25 mg up to 3 times a day if required.",
                        "html": "<p>5&#8211;6.25&#8239;mg up to 3 times a day if required.</p>",
                        "ageGroup": "5&#8211;11 years"
                    },
                    {
                        "textContent": "12.5 mg up to 3 times a day if required.",
                        "html": "<p>12.5&#8239;mg up to 3 times a day if required.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Labyrinthine disorders",
                        "html": "Labyrinthine disorders"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "5 mg 3 times a day, increased if necessary to 30 mg daily in divided doses, dose to be increased gradually, then reduced to 5&#8211;10 mg daily, dose is reduced after several weeks.",
                        "html": "<p>5&#8239;mg 3 times a day, increased if necessary to 30&#8239;mg daily in divided doses, dose to be increased gradually, then reduced to 5&#8211;10&#8239;mg daily, dose is reduced after several weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nausea and vomiting in previously diagnosed migraine",
                        "html": "Nausea and vomiting in previously diagnosed migraine"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth using buccal tablet"
                    ],
                    "textContent": "By mouth using buccal tablet",
                    "html": "By mouth using buccal tablet"
                },
                "child": [
                    {
                        "textContent": "3&#8211;6 mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve.",
                        "html": "<p>3&#8211;6&#8239;mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "3&#8211;6 mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve.",
                        "html": "<p>3&#8211;6&#8239;mg twice daily, tablets to be placed high between upper lip and gum and left to dissolve.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "Doses are expressed as prochlorperazine maleate or mesilate; 1 mg prochlorperazine maleate &#8801; 1 mg prochlorperazine mesilate.",
                "html": "<p>Doses are expressed as prochlorperazine maleate or mesilate; 1&#8239;mg prochlorperazine maleate &#8801; 1&#8239;mg prochlorperazine mesilate.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With intramuscular use in children",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intramuscular"
                    ]
                },
                "textContent": "Injection not licensed for use in children.",
                "html": "<p>Injection not licensed for use in children.</p>"
            },
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With buccal use in children",
                    "html": "With <ph outputclass=\"route\">buccal</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "buccal"
                    ]
                },
                "textContent": "Buccal tablets not licensed for use in children.",
                "html": "<p>Buccal tablets not licensed for use in children.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Avoid oral route in child under 10 kg",
                "html": "Avoid oral route in child under 10&#8239;kg"
            },
            {
                "type": "contraindications",
                "textContent": "children (in psychotic disorders)",
                "html": "children (in psychotic disorders)"
            },
            {
                "type": "contraindications",
                "textContent": "CNS depression",
                "html": "CNS depression"
            },
            {
                "type": "contraindications",
                "textContent": "comatose states",
                "html": "comatose states"
            },
            {
                "type": "contraindications",
                "textContent": "phaeochromocytoma",
                "html": "phaeochromocytoma"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Elderly in adults",
                "html": "Elderly in adults",
                "specificity": {
                    "patientType": "adults"
                }
            },
            {
                "type": "cautions",
                "textContent": "hypotension (more likely after intramuscular injection)",
                "html": "hypotension (more likely after intramuscular injection)"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Dystonic reactions",
                        "html": "Dystonic reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "respiratory depression may occur in susceptible patients",
                        "html": "respiratory depression may occur in susceptible patients",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Acute dystonic reactions",
                "textContent": "Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10 kg) are particularly susceptible.",
                "html": "<p>Phenothiazines can all induce acute dystonic reactions such as facial and skeletal muscle spasms and oculogyric crises; children (especially girls, young women, and those under 10&#8239;kg) are particularly susceptible.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.\n\nAnimal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.\n\nChronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.\n\nPhenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.",
                "html": "<p>There is limited information available on the short- and long-term effects of antipsychotic drugs on the breast-fed infant.</p><p>\n<i>Animal</i> studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</p><p>Chronic treatment with antipsychotic drugs whilst breast-feeding should be avoided unless absolutely necessary.</p><p>Phenothiazine derivatives are sometimes used in breast-feeding women for short-term treatment of nausea and vomiting.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Can precipitate coma; phenothiazines are hepatotoxic.",
                "html": "<p>Can precipitate coma; phenothiazines are hepatotoxic.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Start with small doses in severe renal impairment because of increased cerebral sensitivity.",
                "html": "<p>Start with small doses in severe renal impairment because of increased cerebral sensitivity.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With buccal use",
                    "html": "With <ph outputclass=\"route\">buccal</ph> use",
                    "routes": [
                        "buccal"
                    ]
                },
                "textContent": "Buccal tablets are placed high between upper lip and gum and left to dissolve.",
                "html": "<p>Buccal tablets are placed high between upper lip and gum and left to dissolve.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "With buccal use",
                    "html": "With <ph outputclass=\"route\">buccal</ph> use",
                    "routes": [
                        "buccal"
                    ]
                },
                "textContent": "Patients or carers should be given advice on how to administer prochlorperazine buccal tablets.",
                "html": "<p>Patients or carers should be given advice on how to administer prochlorperazine buccal tablets.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "suppository"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74816",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74803",
                "label": "Buccal tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74823",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74838",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP107735",
                "label": "Prescribing in palliative care",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78221",
                "label": "Nausea and labyrinth disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_382",
                "label": "Prochlorperazine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74816",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74803",
                "label": "Buccal tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74823",
                "label": "Oral solution",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74838",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}